CTLA4 and metastatic melanoma: It has been shown that combining an anti-CTLA-4 mAb (ipilimumab) with an anti-PD-L1 mAb (nivolumab) can help achieve satisfactory results in metastatic melanoma, metastatic CRC, and advanced renal cell carcinoma (34).